SEC Company Response from PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075) (PMCB) — May 5, 2014

PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075)
Date: May 5, 2014 · CIK: 0001157075 · Accession: 0001019687-14-001641

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-68008

Date

May 5, 2014

Author

Kenneth L. Waggoner

Form

CORRESP

Company

PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075)

Letter

Securities and Exchange Commission Nuvilex, Inc. Form 10-K for the fiscal year ended April 30, 2013 Filed July 29, 2013 File No. 333-68008

Dear Ms. De Rosa:

This is in reference to the comment letter issued by the Staff of the Securities and Exchange Commission on April 24, 2014 relating to our Form 10-K for the fiscal year ended April 30, 2013 (“Comment Letter”). I was in Europe on business for Nuvilex at the time of our first telephone conversation about the Comment Letter and am unable to return to my office in Silver Spring, Maryland until May 6. This results in me not being in a position to commence preparing our response until that time. In line with our conversation this morning, we respectfully request an extension of time to respond to the Comment Letter until May 24, 2014.

Very truly yours,
NUVILEX, INC.

Show Raw Text

CORRESP
1
filename1.htm

NUVILEX, INC.

12510 Prosperity Drive, Suite 310

Silver Spring, Maryland

20904

May 5, 2014

Ms. Christina De Rosa

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

    Re:

    Nuvilex, Inc.

Form 10-K for the fiscal year ended April 30, 2013

Filed July 29, 2013

File No. 333-68008

Dear Ms. De Rosa:

This is in reference to the comment letter issued by the Staff
of the Securities and Exchange Commission on April 24, 2014 relating to our Form 10-K for the fiscal year ended April 30, 2013
(“Comment Letter”). I was in Europe on business for Nuvilex at the time of our first telephone conversation about the
Comment Letter and am unable to return to my office in Silver Spring, Maryland until May 6. This results in me not being in a position
to commence preparing our response until that time. In line with our conversation this morning, we respectfully request an extension
of time to respond to the Comment Letter until May 24, 2014.

Very truly yours,

NUVILEX, INC.

By:   /s/ Kenneth L. Waggoner_______

Name: Kenneth L. Waggoner

Title: Chief Executive Officer, President and General Counsel

SecProbe.io